Drug: Abilify
Company: Bristol-Myers Squibb
Total spend Q1, 2012: $35.9 million
Total spend Q1, 2011: $29.7 million
Watch the TV commercial here >>

While it got itself into trouble early with this atypical antipsychotic, in the long run it has paid off handsomely for Bristol-Myers Squibb ($BMY). Abilify placed third in drugs.com's first-quarter ranking of top selling drugs at $1.34 billion. Pretty impressive since sales in all of last year were $2.8 billion, suggesting that the advertising is paying off. It has not always been smooth sailing on this product. Abilify was the focus of the company's 2007, $515 million settlement agreement with the Justice Department, which said the company targeted sales at dementia patients and adolescents, in whom use was unapproved at the time. Bristol-Myers licenses the drug from Japan's Otsuka Pharmaceutical and has patent protection in the U.S. into 2015.


Suggested Articles

Mylan recalls one lot of the injectable antibiotic daptomycin after discovering particles in a single-dose vial.

AbbVie's Allergan received a positive early ruling in its long-running trade secrets dispute with Evolus over a competitor to blockbuster Botox.

As Amgen ramps up clinical trials of its psoriasis drug Otezla in COVID-19, it might also be studying its blockbuster Enbrel in fighting the virus.